Trials Sponsors Conditions Drugs Pricing

Conditions

Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment

Keywords

NSCLCLeptomeningeal MetastasesLeptomeningeal CarcinomatosisMeningeal MetastasesEGFROsimertinib, Zorifertinib

Outcome Measures

Primary Outcomes (1)

Determination of Recommended Dose Based on Incidence of Dose-Limiting Toxicities (DLTs)
A composite endpoint to determine the recommended dose of Zorifertinib in combination with Osimertinib. This is based on the occurrence of protocol-defined Dose-Limiting Toxicities (DLTs) within treatment. The Recommended Dose (RD) is the highest dose level at which the DLT rate is deemed acceptable by the Safety Review Committee (SRC) for further evaluation in the expansion cohort.
During the first 21 days of continuous administration for each participant in the dose-escalation phase.

Secondary Outcomes (14)

Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
From first dose until last dose (up to 12 months).
Objective Response Rate (ORR) for Leptomeningeal Metastases (per RANO-LM)
From first dose until disease progression or death from any cause, assessed up to 12 months.
Leptomeningeal Progression-Free Survival (LM-PFS) (per RANO-LM)
From first dose until leptomeningeal progression or death from any cause, assessed up to 12 months.
Leptomeningeal Progression-Free Survival (LM-PFS) Rate at 3, 6, and 9 Months
Assessed at 3, 6, and 9 months from first dose.
Overall Survival (OS) Rate at 3, 6, and 9 Months
Assessed at 3, 6, and 9 months from first dose.
+9 more secondary outcomes

Other Outcomes (1)

Correlation of Biomarker Status in Cerebrospinal Fluid (CSF) with Clinical Efficacy
CSF samples for analysis are collected at Screening, at Week 6 (Cycle 2 Day 1 of a 21-day cycle), and at the time of suspected disease progression; efficacy outcomes are assessed throughout the study, up to 12 months.

Study Arms (1)

Zorifertinib + Osimertinib (Dose Escalation)

EXPERIMENTAL

All enrolled participants will receive the investigational combination therapy of Zorifertinib and Osimertinib. This is a Phase 1 study consisting of a dose escalation part (Part A) and a dose expansion part (Part B). In Part A, Zorifertinib dose will be escalated (starting at 100 mg twice daily) alongside a fixed dose of Osimertinib (80 mg once daily) using a "3+3" design to determine the recommended dose. In Part B, additional participants will receive the combination at the recommended dose to further evaluate safety, efficacy, and pharmacokinetics. Treatment continues until disease progression, unacceptable toxicity, or meeting other discontinuation criteria.

Drug: Zorifertinib and Osimertinib Combination Therapy

Interventions

Zorifertinib and Osimertinib Combination TherapyDrug

Zorifertinib is an oral tablet (50 mg or 100 mg). Osimertinib is an oral tablet (80 mg). In this Phase 1 study, all participants will receive the combination. Osimertinib is given at a fixed dose of 80 mg once daily. Zorifertinib is given twice daily, with dose levels under evaluation (starting at 100 mg BID, potentially escalating to 150 mg BID, 200 mg BID, or higher). Dose escalation follows a "3+3" design based on dose-limiting toxicity (DLT) assessment in the first 21-day cycle. Treatment continues until disease progression, unacceptable toxicity, or meeting other discontinuation criteria.

Also known as: AZD3759, AZD9291

Zorifertinib + Osimertinib (Dose Escalation)

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
Zorifertinib and Osimertinib Combination Therapy
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

The patient or the guardian is required to understand and sign the informed consent form of this study.
During the screening period, subjects must have a previous histological or cytological diagnosis of NSCLC with a sensitising EGFR mutation (including L858R and/or Exon19Del).

Sponsors & Collaborators

Alpha Biopharma (Jiangsu) Co., Ltd.
Industrylead

Study Sites (5)

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China

RECRUITING

Jie Wang, M.D.CONTACT+86 13910704699 zlhuxi@163.com

The First Affiliated Hospital of China Medical University

Shengyang, City, 110001, China

RECRUITING

Mingfang Zhao Chief Physician, DoctorCONTACT13644055129

Related Publications (21)

Zhou Q, Song Y, Zhang X, Chen GY, Zhong DS, Yu Z, Yu P, Zhang YP, Chen JH, Hu Y, Feng GS, Song X, Shi Q, Yang LL, Zhang PH, Wu YL. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). BMC Cancer. 2017 Jul 3;17(1):462. doi: 10.1186/s12885-017-3451-x.
PMID: 28673332RESULT
Yin K, Li YS, Zheng MM, Jiang BY, Li WF, Yang JJ, Tu HY, Zhou Q, Zhong WZ, Yang XN, Chen HJ, Yan HH, Li LL, Wu YL, Zhang XC. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases. Lung Cancer. 2019 May;131:134-138. doi: 10.1016/j.lungcan.2019.03.015. Epub 2019 Mar 18.
PMID: 31027690RESULT

MeSH Terms

Conditions

Meningeal Carcinomatosis

Interventions

AZD3759osimertinib

Condition Hierarchy (Ancestors)

Meningeal NeoplasmsCentral Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsNervous System Diseases

Central Study Contacts

John Ge, M.D

CONTACT

+86 (0)21-63862197 john.ge@alphabiopharma.com.cn

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SEQUENTIAL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 4, 2025

First Posted

January 23, 2026

Study Start

January 31, 2026

Actual (reported)

Primary Completion

April 23, 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

You may not qualify if:

Subjects who plan to receive brain radiotherapy or intrathecal injection during the period from signing ICF to study medication.
Radiotherapy history within 28 days before study drug administration is not allowed for enrollment, and palliative radiation to the skeleton occurring within 14 days before study drug administration is also not allowed for enrollment.
Subjects who have undergone major surgery (e.g. intrathoracic, intraperitoneal or pelvic surgery) within 4 weeks prior to the first dose of study treatment or who have not yet recovered from the side effects associated with such surgery are not allowed to be enrolled.
In addition to NSCLC, there are other malignant tumors, or a history of other malignant tumors within 5 years, except for the following cases: Complete resection of skin basal cell and squamous cell carcinoma and radical resection of any type of carcinoma in situ.
Suffering from clinically significant and uncontrollable cardiac disorder and/or heart-related events within 6 months, such as:
(1) Unstable angina within 6 months before the screening period; (2) Myocardial infarction within 6 months before the screening period; (3) Documented history of heart failure (NYHA Class III-IV) or left ventricular ejection fraction (LVEF) \< 50%; (4) Uncontrollable hypertension: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, with or without antihypertensive drug treatment; the drugs are allowed to be adjusted before the screening period; (5) Ventricular arrhythmia; (6) Supraventricular or sinus arrhythmias but difficult to control with drugs; (7) Arrhythmias that cannot be controlled by other drugs; (8) QTcF \>470 ms (mean value of three readings corrected using the Fridericia formula) during the screening period.
(9) The patient has any factors that increase the risk of QTc prolongation or arrhythmic events, such as electrolyte disturbances, including: Grade 2 or higher hypokalemia according to CTCAE (electrolyte disturbances should be corrected to ≤Grade 1 according to CTCAE and documented before the first dose); heart failure, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death in a first-degree relative under the age of 40, or any concomitant medication known to prolong the QT interval and lead to torsades de pointes.
\. Suffering from gastrointestinal disorders or serious impairment of gastrointestinal function, which may significantly affect drug absorption (e.g. ulcerative diseases, uncontrollable nausea, or vomiting, diarrhea, or malabsorption syndrome).
\. Unable to discontinue the following medications before the start of the study drug and during the study according to the withdrawal period provided in Appendix 13.6 (see Appendix 13.6 for specific withdrawal periods):
Strong CYP3A4 inducers or inhibitors;
Drugs mainly metabolised by CYP3A4;
Drugs that may cause QT interval prolongation or torsade de pointe. 8. Patients with a previous or concurrent HIV infection are not allowed to enroll. Patients who are HCV antibody positive can be enrolled if HCV-RNA is undetectable (the lower limit of normal for HCV-RNA detection is based on the test values of each site) and there is no concurrent hepatitis B virus (HBV) infection. HBV-infected individuals are allowed to be enrolled if they meet the following criteria: 1) Patients with active hepatitis B must meet the following conditions: Antiviral treatment is given for at least 6 weeks before starting study treatment, HBV DNA must be \<100 IU/mL, and ALT and AST levels must be \<ULN; 2) Patients with resolved hepatitis B or chronic hepatitis B must meet the following criteria: Patients have received prophylactic antiviral treatment for at least 2-4 weeks before the start of study treatment, transaminases have been below ULN for \>6 months, and HBV DNA is below 100 IU/mL (if in an inactive carrier state) 9. Women who are pregnant or lactating. Women of childbearing potential are required to use highly effective contraceptive methods during the dosing period and for 3 months after discontinuation of the drug. Fertile males must also use highly effective contraceptive methods during the dosing period and for 6 months after discontinuation of the drug.
A woman of child-bearing potential is defined as a non-postmenopausal woman who has experienced menarche and has not undergone sterilization (hysterectomy or bilateral salpingo-oophorectomy) or has no other causes of permanent infertility (such as Mullerian agenesis) determined by the investigator. Postmenopause is defined as amenorrhea ≥ 12 months without other biological or physiological reasons.
\. Due to existence of other serious, acute or chronic medical diseases (e.g. uncontrollable diabetes or psychic disorder or abnormal laboratory tests), the investigators judged that participating in the study treatment may bring more risks to the subjects or make it difficult to explain the study results.
\. Previously suffering from interstitial lung disease, including clinically significant radiation pneumonia (e.g. affecting daily life or requiring treatment intervention).
+3 more criteria

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (14)

Other Outcomes (1)

Study Arms (1)

Zorifertinib + Osimertinib (Dose Escalation)

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (5)

Related Publications (21)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (14)

Other Outcomes (1)

Study Arms (1)

Zorifertinib + Osimertinib (Dose Escalation)

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (5)

Related Publications (21)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations